Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.
32 patients with coagulation factor deficiencies and likely to be susceptible to non-A, non-B hepatitis (NANBH) virus infection were treated with a total of 20 batches of a factor VIII concentrate and 10 batches of a factor IX concentrate, both heated at 80 degrees C for 72 h in the freeze-dried state. Serial measurements of serum aminotransferase levels for 4 months revealed no patterns of rises attributable to NANBH. Severe dry heating appears to have reduced the risk of NANBH transmission from about 90% in untreated concentrates to a statistically determined rate of 0-9%. No evidence was found in recipients of infection with hepatitis B or human immunodeficiency virus.
D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D004340:Drug Contamination; D005069:Evaluation Studies as Topic; D005164:Factor IX / Q000009:adverse effects* / Q000627:therapeutic use; D005169:Factor VIII / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D005612:Freeze Drying; D006526:Hepatitis C / Q000097:blood / Q000635:transmission*; D006525:Hepatitis, Viral, Human / Q000635:transmission*; D006358:Hot Temperature; D006801:Humans; D008297:Male; D013696:Temperature; D013997:Time Factors; D000637:Transaminases / Q000097:blood
D005169:Factor VIII; D005164:Factor IX; D000637:Transaminases